US › Healthcare

Galmed Pharmaceuticals Ltd (GLMD)

US · Healthcare · Biotechnology

$3.84-4.71%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.7M

EPS

$-2.86

EPS estimate

$-3.12

EPS came in at -2.86 against a street estimate of -3.12 — a beat of 8.3%.

Key statistics

Market cap

$4.9M

Forward P/E

0.0

P/B

0.32

Book value

$16.91

EPS (TTM)

$-14.29

52-week high

$5.45

52-week low

$0.41

50-day MA

$4.33

200-day MA

$5.17

Beta

0.67

Analyst view

Analysts rate Galmed Pharmaceuticals Ltd a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

3.04%

Institutions

1.89%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	1.04%
XTX Topco Ltd	0.27%
Jane Street Group LLC	0.20%
TWO SIGMA SECURITIES, LLC	0.14%
UBS Group AG	0.03%
BNP Paribas Arbitrage, SA	0.01%
Morgan Stanley - Brokerage Accounts	0.00%
Wells Fargo & Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Galmed Pharmaceuticals Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.